Skip to content

DMT: all studies

Page 59 of 160: studies 581 to 590 of 1,593, newest first. Back to the DMT overview

Research

Commentary: Evidence-Informed Recommendation to Achieve Approximate Parity in the Allowed Number of Doses for Common Psychedelics.

Journal of Psychoactive Drugs 2024 Kelan Thomas, Robert L. Jesse, Nicky J. Mehtani et al. 4 citations

In recent years, policymakers have proposed and implemented regulatory changes promoting the deprioritization, decriminalization, or state-level legalization of one or more psychedelic substances, usually referencing data from clinical trials as reasons to support liberalizing drug control policies. As psychedelic policies continue to be drafted, personal possession limits may be considered for...

Psilocybin and Other Classic Psychedelics in Depression.

Current Topics in Behavioral Neurosciences 2024 D J Nutt, Joseph Peill, B Weiss et al. 30 citations

Psychedelic drugs such as psilocybin and ketamine are returning to clinical research and intervention across several disorders including the treatment of depression. This chapter focusses on psychedelics that specifically target the 5-HT2A receptor such as psilocybin and DMT. These produce plasma-concentration related psychological effects such as hallucinations and out of body experiences,...

Shared functional connectome fingerprints following ritualistic ayahuasca intake.

Neuroimage 2024 Pablo Mallaroni, Natasha L. Mason, Lilian Kloft et al. 17 citations

The knowledge that brain functional connectomes are unique and reliable has enabled behaviourally relevant inferences at a subject level. However, whether such "fingerprints" persist under altered states of consciousness is unknown. Ayahuasca is a potent serotonergic psychedelic which produces a widespread dysregulation of functional connectivity. Used communally in religious ceremonies, its...

DOI: 10.1016/j.neuroimage.2023.120480 (opens in new tab) Full text (opens in new tab) DMT Entheogens Brain connectivity connectome Neuroimaging FMRI +8

Present and future of metabolic and metabolomics studies focused on classical psychedelics in humans

Biomedicine & Pharmacotherapy December 31, 2023 David Fabregat-Safont, Alex Gomez-Gomez, Francisco Madrid-Gambin et al.

Psychedelics are classical hallucinogen drugs that induce a marked altered state of consciousness. In recent years, there has been renewed attention to the possible use of classical psychedelics for the treatment of certain mental health disorders. However, further investigation to better understand their biological effects in humans, their mechanism of action, and their metabolism in humans is...

Present and future of metabolic and metabolomics studies focused on classical psychedelics in humans.

Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie December 31, 2023 Francisco Madrid-Gambin, David Fabregat-Safont, Alex Gomez-Gomez et al. 12 citations

Psychedelics are classical hallucinogen drugs that induce a marked altered state of consciousness. In recent years, there has been renewed attention to the possible use of classical psychedelics for the treatment of certain mental health disorders. However, further investigation to better understand their biological effects in humans, their mechanism of action, and their metabolism in humans is...

The possible place for psychedelics in pharmacotherapy of mental disorders.

Pharmacological Reports December 1, 2023 Adam Wojtas 10 citations

Since its emergence in the 1960s, the serotonergic theory of depression bore fruit in the discovery of a plethora of antidepressant drugs affecting the lives of millions of patients. While crucial in the history of drug development, recent studies undermine the effectiveness of currently used antidepressant drugs in comparison to placebo, emphasizing the long time it takes to initiate the...

Ayahuasca: A review of historical, pharmacological, and therapeutic aspects.

Psychiatry and Clinical Neurosciences Reports December 1, 2023 Simon Ruffell, Max Crosland-Wood, Rob Palmer et al. 37 citations

Ayahuasca is a psychedelic plant brew originating from the Amazon rainforest. It is formed from two basic components, the Banisteriopsis caapi vine and a plant containing the potent psychedelic dimethyltryptamine (DMT), usually Psychotria viridis. Here we review the history of ayahuasca and describe recent work on its pharmacology, phenomenological responses, and clinical applications. There...

Bedside to bench: the outlook for psychedelic research

Frontiers in Pharmacology October 2, 2023 Victor P Acero, Emily S Cribas, Kevin D Browne et al. 20 citations

There has recently been a resurgence of interest in psychedelic compounds based on studies demonstrating their potential therapeutic applications in treating post-traumatic stress disorder, substance abuse disorders, and treatment-resistant depression. Despite promising efficacy observed in some clinical trials, the full range of biological effects and mechanism(s) of action of these compounds...

Natural psychedelics in the treatment of depression; a review focusing on neurotransmitters.

Fitoterapia September 1, 2023 Samane Jahanabadi, Shayan Amiri, Mehdi Karkeh-Abadi et al. 14 citations

Natural psychedelic compounds are emerging as potential novel therapeutics in psychiatry. This review will discuss how natural psychedelics exert their neurobiological therapeutic effects, and how different neurotransmission systems mediate the effects of these compounds. Further, current therapeutic strategies for depression, and novel mechanism of action of natural psychedelics in the...

A Brief Review on the Potential of Psychedelics for Treating Alzheimer’s Disease and Related Depression

International Journal of Molecular Sciences August 7, 2023 Alexander Pilozzi, Simmie Foster, David Mischoulon et al. 16 citations

Alzheimer’s disease (AD), the most common form of senile dementia, is poised to place an even greater societal and healthcare burden as the population ages. With few treatment options for the symptomatic relief of the disease and its unknown etiopathology, more research into AD is urgently needed. Psychedelic drugs target AD-related psychological pathology and symptoms such as depression. Using...